Has Amy Devore, MD received payments from drug or device companies?

Yes. Drug and device makers reported $39,766 in general payments to Amy Devore, MD across 485 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amy Devore, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amy Devore, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amy Devore, MD

Dermatology · Mount Airy, NCNPI 1063559441

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $25,625 of the $39,766 with a category attached, or 64.4%. Pfizer accounts for 81.4% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $31,817 and has fallen 96.9% since, to $983 in 2025. Among dermatology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,766in general payments, 2019–2025

Across 485 payments — averaging $81.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$32K
AbbVie$2K
Johnson & Johnson$2K
Sanofi$486
Amgen$481
Lilly USA, LLC$375
plus $3K from 20 others

What the payments were for

Speaking & faculty fees$25,62564%
Travel & lodging$5,60414%
Food & beverage$7,92220%
Education$6162%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	55	$32,368
AbbVie	132	$1,780
Johnson & Johnson	65	$1,553
Sanofi	21	$486
Amgen	35	$481
Lilly USA, LLC	18	$375
UCB, Inc.	15	$312
Novartis	15	$261
Regeneron Healthcare Solutions, Inc.	12	$250
E.r. Squibb & Sons, L.L.C.	13	$225
Sun Pharmaceutical Industries Inc.	10	$223
Galderma Laboratories, L.p.	13	$206
Arcutis Biotherapeutics, Inc.	11	$201
Biofrontera Inc.	10	$162
Boehringer Ingelheim	7	$156
LEO Pharma Inc.	7	$142
Bristol Myers Squibb	20	$136
Almirall LLC	6	$103
Dermavant Sciences, Inc.	6	$87
Incyte Corporation	3	$78
Organogenesis Inc.	2	$51
Ortho Dermatologics, A Division Of Bausch Health US, LLC	2	$34
VYNE Pharmaceuticals Inc.	1	$26
KCI USA, Inc.	1	$25
Organon	3	$24
Strata Skin Sciences, Inc.	2	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EUCRISA$31,555

How this compares

$39,766 in reported general payments places this provider in the 90th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina →

Medicare billing

Part B allowed, 2024

$359,466

Medicare patients

1,208

Services billed

11,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Skyrizi PenRisankizumab-Rzaa	48	$974,304
Humira(Cf) PenAdalimumab	27	$257,421
Cosentyx Sensoready PenSecukinumab	12	$174,259
Dupixent PenDupilumab	33	$122,839
Fluorouracil	91	$7,227
Fluocinonide	169	$6,236
Ketoconazole	389	$4,942
Metronidazole	82	$4,732
Ivermectin	24	$4,364
Clobetasol Propionate	97	$3,706
ValacyclovirValacyclovir Hcl	100	$3,699
Triamcinolone Acetonide	286	$3,149
Doxycycline Hyclate	93	$2,750
Calcipotriene	14	$1,886
Mupirocin	230	$1,850

Paid to pharmacies, not to this prescriber.

Other dermatology in Mount Airy

Steven FeldmanWinston Salem$3.4M
Nicole SeminaraHuntersville$1.4M
Andrew LeeElkin$702K
Christopher SayedChapel Hill$690K
William HooverConcord$594K
Patrick McElgunnCharlotte$565K
George MagelHickory$554K
Muneeb ShahClinton$451K
John SoderbergCary$398K
Rosalyn GeorgeWilmington$346K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →